<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22494" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pantothenate Kinase-Associated Neurodegeneration (PKAN)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Maria R.</given-names>
          </name>
          <aff>Tulane Hospital , Louisiana</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zulfiqar</surname>
            <given-names>Hassam</given-names>
          </name>
          <aff>Hamad Medical Corporation, Doha, Qatar</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Syed Rizwan A.</given-names>
          </name>
          <aff>Tulane Un, Un Med Center New Orleans</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rizwan Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22494.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pantothenate kinase-associated neurodegeneration (PKAN),&#x000a0;formerly known as&#x000a0;Hallervorden-Spatz disease, is a rare autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain nuclei and characterized by progressive extrapyramidal dysfunction and dementia. Classically, the disease presents between ages 7 and 15 years. However, the disease onset has been reported in all age groups, including infancy and adulthood. As PKAN has an autosomal mode of inheritance, each sibling of an individual has a 25% chance of being affected and a 50% chance of being an asymptomatic carrier. This activity reviews the evaluation and management of pantothenate kinase-associated neurodegeneration and highlights the role of the interprofessional team in the care of affected patients and their families.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of pantothenate kinase-associated neurodegeneration.</p></list-item><list-item><p>Describe the typical presentation of a patient with pantothenate kinase-associated neurodegeneration.</p></list-item><list-item><p>Describe the risk of the affected child's mother having another child with pantothenate kinase-associated neurodegeneration.</p></list-item><list-item><p>Describe the importance of improving care coordination amongst interprofessional team members to improve care for patients affected by pantothenate kinase-associated neurodegeneration and to provide appropriate counsel to their families.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22494&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22494">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22494.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pantothenate kinase-associated neurodegeneration (PKAN),&#x000a0;formerly known as&#x000a0;Hallervorden-Spatz disease,&#x000a0;is a rare autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain nuclei and characterized by progressive extrapyramidal dysfunction and dementia.<xref ref-type="bibr" rid="article-22494.r1">[1]</xref><xref ref-type="bibr" rid="article-22494.r2">[2]</xref><xref ref-type="bibr" rid="article-22494.r3">[3]</xref></p>
      </sec>
      <sec id="article-22494.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>PKAN&#x000a0;was first described in 1922 by&#x000a0;2 German physicians, Hallervorden and Spatz, as a form of familial brain degeneration characterized by cerebral iron deposition. PKAN is a subset of neurodegeneration with brain iron accumulation (NBIA), in the basal ganglia, with subsequent variable neurological dysfunction.&#x000a0;Numerous genes (at least 10)&#x000a0;have been identified, resulting in a variety of specific diseases.</p>
        <p>The exact etiology of&#x000a0;PKAN is not well understood. One of the proposed hypotheses is that aberrant oxidation of lipofuscin to neuromelanin and insufficient cysteine dioxygenase lead to abnormal iron accumulation in the brain. While portions of the globus pallidus and pars reticularis of substantia nigra have relatively higher&#x000a0;iron content in healthy individuals, individuals with&#x000a0;PKAN have excessive amounts of iron accumulated in these nuclei.</p>
        <p>A role for mutation in the&#x000a0;<italic toggle="yes">PANK2</italic>&#x000a0;gene (band 20p13) accounts for most inherited&#x000a0;PKAN cases as the etiology of&#x000a0;PKAN&#x000a0;in various studies. &#x000a0;Mutations result in an autosomal recessive inborn error of coenzyme A metabolism with a resultant deficiency of pantothenate kinase enzyme, which may lead to the accumulation of cysteine and cysteine-containing compounds in the basal ganglia. This causes chelation of iron in the globus pallidus and other basal ganglia and rapid auto-oxidation of cysteine in the presence of iron with subsequent free radical production. Pathologic examination reveals characteristic rust-brown discoloration of the globus pallidus and substantia nigra pars reticularis due to underlying iron deposition and a reduction in the size of these nuclei. Generalized atrophy of the brain parenchyma may be seen in severely advanced cases.<xref ref-type="bibr" rid="article-22494.r4">[4]</xref><xref ref-type="bibr" rid="article-22494.r5">[5]</xref></p>
      </sec>
      <sec id="article-22494.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>According to some studies prevalence of PKAN is 1-9/1000000. The classic presentation is in the late part of the first decade or the early part of the second decade, between ages 7 and 15 years. However, the disease onset has been reported in all age groups, including infancy and adulthood.&#x000a0;</p>
      </sec>
      <sec id="article-22494.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The mechanism by which basal ganglia iron uptake is increased in PKAN&#x000a0;is unknown since systemic and cerebrospinal fluid iron levels, as well as plasma ferritin, transferrin, and ceruloplasmin, all are normal. One of the proposed mechanisms is that aberrant oxidation of lipofuscin to neuromelanin and insufficient cysteine dioxygenase leads to abnormal iron in the brain. While portions of the globus pallidus and pars reticularis of substantia nigra have high iron content in healthy individuals, individuals with&#x000a0;PKAN have excess amounts of iron deposited in these nuclei. A role for mutation in the&#x000a0;<italic toggle="yes">PANK2</italic>&#x000a0;gene (band 20p13) accounts for most inherited&#x000a0;PKAN cases in the etiology of&#x000a0;PKAN&#x000a0;in various studies. Mutations result in an autosomal recessive inborn error of coenzyme A metabolism with a resultant deficiency of pantothenate kinase may lead to the accretion of cysteine and cysteine-containing compounds in the basal ganglia. This causes chelation of iron in the globus pallidus and rapid auto-oxidation of cysteine in the presence of iron with subsequent free radical generation.</p>
        <p>Pathologic examination reveals characteristic rust-brown discoloration of the globus pallidus and substantia nigra pars reticularis due to iron deposition and a reduction in the size of the caudate nuclei, substantia nigra, and tegmentum, as well as generalized atrophy of the brain.</p>
        <p>Microscopically marked neuroaxonal and myelin degeneration is a distinctive pathologic feature of PKAN.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ubiquitinated spheroids, which represent swollen axons with vacuolated cytoplasm&#x000a0;inactivated by attachment of ubiquitin, are&#x000a0;found most abundantly in the pallidonigral system&#x000a0;and in the cerebral cortex.</p>
          </list-item>
          <list-item>
            <p>Accumulation of &#x000a0;iron-containing pigment, mostly neuromelanin, and ceroid lipofuscin, in the palladonigral system</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22494.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PKAN is characterized by progressive dystonia, a motor disorder of extrapyramidal type with gait difficulty. In classic form, usually, onset&#x000a0;occurs&#x000a0;in the first decade. Clinical manifestations of PKAN vary from patient to patient.&#x000a0;</p>
        <p>&#x000a0;Patients with this disease suffer from a variety of other neurological symptoms and signs, including:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Extrapyramidal symptoms: dystonia, dysarthria, muscular rigidity, spasms, Parkinson-like symptoms.</p>
          </list-item>
          <list-item>
            <p>Dystonia &#x000a0;(continuous spasms and muscle contractions)- A prominent and early feature</p>
          </list-item>
          <list-item>
            <p>Tremors, rarely bradykinesia (slowness of movement) and Choreoathetosis(involuntary movements in&#x000a0;along&#x000a0;with chorea(irregular migrating contractions) and athetosis (twisting and writhing)</p>
          </list-item>
          <list-item>
            <p>Significant speech disturbances - Can occur early</p>
          </list-item>
          <list-item>
            <p>Dysphagia - A common symptom; caused by rigidity of muscles and &#x000a0;associated corticobulbar abnormality</p>
          </list-item>
          <list-item>
            <p>Dementia - Present in most patients&#x000a0;with PKAN</p>
          </list-item>
          <list-item>
            <p>Visual impairment - Consequence of optic atrophy or retinal degeneration; can be the presenting symptom of the disease, although this is rare</p>
          </list-item>
          <list-item>
            <p>Seizures - Have been reported frequently</p>
          </list-item>
          <list-item>
            <p>Akathesis- (feeling of internal motor restlessness that can present as tension, nervousness, or anxiety)</p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric dysfunction</p>
          </list-item>
          <list-item>
            <p>Optic atrophy</p>
          </list-item>
          <list-item>
            <p>Retinal degeneration</p>
          </list-item>
        </list>
        <p>Approximately 25% of individuals have an 'atypical' presentation with onset later in life (onset mostly in a second and third decade), delay of extrapyramidal dysfunction for several years, and more gradual progression of the disease process. Prominent speech defects, spasticity, and psychiatric disturbances also dominate in the atypical form.&#x000a0;</p>
        <p>Based on the common clinical features, the following diagnostic criteria have been proposed. For a definitive diagnosis, all of the obligate findings and, at minimum, two&#x000a0;of the corroborative findings should be present.</p>
        <p>Obligate features of&#x000a0;PKAN &#x000a0;are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset in the first two decades of life</p>
          </list-item>
          <list-item>
            <p>Progression of signs and symptoms; classic form: loss of ambulation occurring within 10-15 years of onset; atypical form: ambulatory loss occurs within 15-40 years of disease onset.</p>
          </list-item>
          <list-item>
            <p>Evidence of extrapyramidal dysfunction, including one or more of these neurological impairments: dystonia, rigidity, and choreoathetosis.</p>
          </list-item>
        </list>
        <p>Corroborative features are listed as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Corticospinal tract involvement: spasticity, hyperreflexia, and extensor toe signs</p>
          </list-item>
          <list-item>
            <p>Progressive intellectual deterioration</p>
          </list-item>
          <list-item>
            <p>Retinitis pigmentosa and/or optic atrophy( seen with electroretinogram or visual field testing)</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Family history consistent with autosomal recessive inheritance( may include consanguinity)</p>
          </list-item>
          <list-item>
            <p>Hypointense areas on magnetic resonance imaging (MRI) in &#x000a0;the involved &#x000a0;basal ganglia</p>
          </list-item>
          <list-item>
            <p>Abnormal cytosomes in circulating lymphocytes</p>
          </list-item>
          <list-item>
            <p>Red blood cell acanthocytosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22494.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>CT Imaging</bold>
</p>
        <p>CT is&#x000a0;not very helpful in the diagnosis of&#x000a0;PKAN, but rarely hypodensity in the basal ganglia, and some atrophy of the brain has been reported. Calcification in the basal ganglia in the absence of any atrophy has also been described.&#x000a0;</p>
        <p>
<bold>Brain MRI</bold>
</p>
        <p>Brain MRI the standard in the diagnostic evaluation of all forms of neurodegeneration with brain iron accumulation (NBIA). &#x000a0;NBIA has significantly increased the likelihood of a diagnosis of PKAN. Imaging findings are most conspicuous on T2W &#x000a0;sequences which demonstrate hypointensity reflecting areas of iron deposition, mainly in globi pallidi, &#x000a0;pars reticulata of the substantia nigra, and red nuclei. &#x000a0;Studies report that all patients with PANK2 mutations, whether classic or atypical, have&#x000a0;the characteristic radiologic sign known as the "eye of the tiger" on brain MRI, which is evident as bilateral symmetrical, central foci of hyperintense signals in the anteromedial globus pallidus, with a surrounding zone of hypointensity in the globus pallidus on T2W MR scanning. The central T2 relatively hyperintense spot or line within the globi pallidi is due to gliosis and vacuolization. This sign was not reported in patients without PANK2 mutations.&#x000a0; The cortex is usually spared, but&#x000a0;atrophy can be seen in advanced cases.</p>
        <p>
<bold>SWI/T2*</bold>
</p>
        <p>Show susceptibility artifact (blooming low signal) in corresponding areas due to iron accretion. MR spectroscopy shows decreased NAA peak due to neuronal loss and may depict increased myoinositol.&#x000a0;</p>
        <p>
<bold>SPECT Scanning</bold>
</p>
        <p>Iodine-123 (&#x000a0;I)-beta-carbomethoxy-3beta-(4-fluorophenyl) tropane &#x000a0;SPECT scanning and (&#x000a0;I)-iodobenzamide (IBZM)-SPECT scanning have been used in making the diagnosis of Hellervorden Spatz disease but are not commonly used in the clinical setup.</p>
        <p>
<bold>Antenatal Diagnosis &#x000a0;</bold>
</p>
        <p>Prenatal testing for pregnancies at risk is through&#x000a0;DNA testing. Cells are usually obtained by amniocentesis at 15 to 20 weeks of gestation or by chorionic villus sampling at 10 to 13 weeks. At least one mutation in the proband of extracted DNA should be present for a prenatal diagnosis of NBIA. If both pathogenic variants have been found in an affected family member, carrier testing for at-risk relatives is possible by the same technique.</p>
      </sec>
      <sec id="article-22494.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of patients with Hellervorden Spatz disease or PKAN&#x000a0;is mostly symptomatic. The tremors best respond to dopaminergic agents. &#x000a0;For rigidity and spasticity, dopamine agonists and anticholinergic agents alone or in combination may be used. &#x000a0;Intrathecal or oral Baclofen in moderate doses relieves stiffness and spasms and can reduce dystonia. &#x000a0;Intramuscular botulinum toxin has also been used for the alleviation of hypertonicity. &#x000a0;Benzodiazepines have been used for choreoathetotic movements.&#x000a0;Medications such as methscopolamine bromide can be attempted for excessive drooling. Dysarthria could respond to medications employed for rigidity and spasticity. A multidisciplinary team approach, including physical and speech therapy, swallowing evaluation, dietary assessment, gastrostomy tube feeding, and computer-assisted devices, may be used in advanced cases to&#x000a0;improve functional and communication skills.<xref ref-type="bibr" rid="article-22494.r6">[6]</xref><xref ref-type="bibr" rid="article-22494.r7">[7]</xref><xref ref-type="bibr" rid="article-22494.r8">[8]</xref></p>
        <p>Dementia is gradual&#x000a0;and progressive and usually does not&#x000a0;respond to treatments.&#x000a0; Affected individuals with recurrent tongue biting due to severe Oro buccolingual dystonia, bite blocks, and&#x000a0;full-mouth dental extraction may be the only effective measure. &#x000a0;The use of systemic chelating agents, such as desferrioxamine, has been attempted to remove excess iron from the brain, but it didn't prove beneficial.&#x000a0;Research and trials for the administration of coenzyme A and high dosage of pantothenate are still in progress. However, no conclusive data are available.</p>
      </sec>
      <sec id="article-22494.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>GM gangliosidoses</p>
          </list-item>
          <list-item>
            <p>Huntington disease</p>
          </list-item>
          <list-item>
            <p>Juvenile neuronal ceroid lipofuscinosis</p>
          </list-item>
          <list-item>
            <p>Machado-Joseph disease</p>
          </list-item>
          <list-item>
            <p>Neuroacanthocytosis</p>
          </list-item>
          <list-item>
            <p>Neuronal ceroid lipofuscinosis</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22494.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>As&#x000a0;PKAN has an autosomal mode of inheritance, each sibling of an individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being asymptomatic and not a carrier.&#x000a0;</p>
      </sec>
      <sec id="article-22494.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>PKAN is best managed by an interprofessional team that includes nurses, geneticists, and counselors. The disorder has no cure and is progressive. Genetic testing should be offered to the parents, and counseling provided. The prognosis for most patients is very poor.</p>
      </sec>
      <sec id="article-22494.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22494&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22494">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/pantothenate-kinase-associated-neurodegeneration-pkan-pantothenate-kinase-associated-neurodegeneration-pkan/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22494">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22494/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22494">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22494.s13">
        <fig id="article-22494.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bilateral hypointense globi pallidi due to iron deposition in a patient of PKAN on T2W MRI Contributed by Jinnah Hospital; Lahore, Pakistan</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG-20161225-WA0017" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22494.s14">
        <title>References</title>
        <ref id="article-22494.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakpichaisakul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saengow</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Suwanpratheep</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rongnoparat</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Panthan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trachoo</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Novel PANK2 mutation discovered among South East Asian children living in Thailand affected with pantothenate kinase associated neurodegeneration.</article-title>
            <source>J Clin Neurosci</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>66</volume>
            <fpage>187</fpage>
            <page-range>187-190</page-range>
            <pub-id pub-id-type="pmid">31088771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marshall</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Escolar</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jinnah</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Klopstock</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kruer</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Videnovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robichaux-Viehoever</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swett</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Revicki</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Lenderking</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-149</page-range>
            <pub-id pub-id-type="pmid">30838313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvarez-Cordoba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villanueva-Paz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villal&#x000f3;n-Garc&#x000ed;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Povea-Cabello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Rivero</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Talaver&#x000f3;n-Rey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abril-Jaramillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vintimilla-Tosi</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Alc&#x000e1;zar</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Precision medicine in pantothenate kinase-associated neurodegeneration.</article-title>
            <source>Neural Regen Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>1177</fpage>
            <page-range>1177-1185</page-range>
            <pub-id pub-id-type="pmid">30804242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Clinical characteristics and molecular pathogenesis of pantothenate kinase-associated neurodegenerative disease].</article-title>
            <source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source>
            <year>2019</year>
            <month>Feb</month>
            <day>10</day>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-178</page-range>
            <pub-id pub-id-type="pmid">30703242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging, susceptibility weighted imaging and quantitative susceptibility mapping findings of pantothenate kinase-associated neurodegeneration.</article-title>
            <source>J Clin Neurosci</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>59</volume>
            <fpage>20</fpage>
            <page-range>20-28</page-range>
            <pub-id pub-id-type="pmid">30392836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razmeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habibi</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Orooji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moradiankokhdan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Razmeh</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments.</article-title>
            <source>Neurol Int</source>
            <year>2018</year>
            <month>Mar</month>
            <day>30</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>7516</fpage>
            <pub-id pub-id-type="pmid">29844889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jackowski</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A therapeutic approach to pantothenate kinase associated neurodegeneration.</article-title>
            <source>Nat Commun</source>
            <year>2018</year>
            <month>Oct</month>
            <day>23</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>4399</fpage>
            <pub-id pub-id-type="pmid">30352999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22494.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garzuly</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[From the Hallervorden-Spatz eponym to the molecular terminology].</article-title>
            <source>Orv Hetil</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>158</volume>
            <issue>43</issue>
            <fpage>1723</fpage>
            <page-range>1723-1727</page-range>
            <pub-id pub-id-type="pmid">29135293</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
